Risk Factors for Tuberculosis After Highly Active Antiretroviral Therapy Initiation in the United States and Canada: Implications for Tuberculosis Screening

Background. Screening for tuberculosis prior to highly active antiretroviral therapy (HAART) initiation is not routinely performed in low-incidence settings. Identifying factors associated with developing tuberculosis after HAART initiation could focus screening efforts. Methods. Sixteen cohorts in...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of infectious diseases Vol. 204; no. 6; pp. 893 - 901
Main Authors Sterling, Timothy R., Lau, Bryan, Zhang, Jinbing, Freeman, Aimee, Bosch, Ronald J., Brooks, John T., Deeks, Steven G., French, Audrey, Gange, Stephen, Gebo, Kelly A., Gill, M. John, Horberg, Michael A., Jacobson, Lisa P., Kirk, Gregory D., Kitahata, Mari M., Klein, Marina B., Martin, Jeffrey N., Rodriguez, Benigno, Silverberg, Michael J., Willig, James H., Eron, Joseph J., Goedert, James J., Hogg, Robert S., Justice, Amy C., McKaig, Rosemary G., Napravnik, Sonia, Thorne, Jennifer, Moore, Richard D.
Format Journal Article
LanguageEnglish
Published Oxford Oxford University Press 15.09.2011
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Background. Screening for tuberculosis prior to highly active antiretroviral therapy (HAART) initiation is not routinely performed in low-incidence settings. Identifying factors associated with developing tuberculosis after HAART initiation could focus screening efforts. Methods. Sixteen cohorts in the United States and Canada contributed data on persons infected with human immunodeficiency virus (HIV) who initiated HAART December 1995-August 2009. Parametric survival models identified factors associated with tuberculosis occurrence. Results. Of 37 845 persons in the study, 145 were diagnosed with tuberculosis after HAART initiation. Tuberculosis risk was highest in the first 3 months of HAART (20 cases; 215 cases per 100 000 person-years; 95% confidence interval [CI]: 131-333 per 100 000 person-years). In a multivariate Weibull proportional hazards model, baseline CD4+ lymphocyte count <200, black race, other nonwhite race, Hispanic ethnicity, and history of injection drug use were independently associated with tuberculosis risk. In addition, in a piece-wise Weibull model, increased baseline HIV-1 RNA was associated with increased tuberculosis risk in the first 3 months; male sex tended to be associated with increased risk. Conclusions. Screening for active tuberculosis prior to HAART initiation should be targeted to persons with baseline CD4 <200 lymphocytes/mm³ or increased HIV-1 RNA, persons of nonwhite race or Hispanic ethnicity, history of injection drug use, and possibly male sex.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Presented in part: 15th Conference on Retroviruses and Opportunistic Infections (CROI), 3–6 February 2008, Boston, MA, Abstract 1001; and the XVII International AIDS Conference, 4 August 2008, Mexico City, Mexico, Abstract MOAB0304.
Potential conflicts of interest: T. R. S. reports receiving grant support from Pfizer and Bristol-Myers Squibb. S. G. D. reports receiving consulting fees from GlaxoSmithKline, Roche, Gilead, and Boehringer-Ingelheim and grant support from Merck, Gilead, Bristol-Myers Squibb, and Pfizer. M. J. G. reports receiving consulting fees from Gilead, Abbott, Merck, Boehringer-Ingelheim, Tibotec, and Pfizer and grant support from GlaxoSmithKline, Abbott, Canadian Institutes of Health Research, Tibotec, and Pfizer. M. B. K. reports receiving consulting fees from GlaxoSmithKline, Abbott, Pfizer, and Boehringer-Ingelheim; lecture fees from Abbott, Gilead, Tibotec, Bristol-Myers Squibb, and GlaxoSmithKline; and research support from Canadian Institutes of Health Research/Fonds de la Recherche en Santé du Québec, Canadian HIV Trials Network, Ontario HIV Treatment Network, and Schering Plough Canada. B. R. reports receiving consulting fees from Gilead and Bristol-Myers Squibb, lecture fees from Bristol-Myers Squibb, and grant support from STERIS. J. H. W. reports receiving consulting fees and/or research funding from Bristol-Myers Squibb, Gilead Sciences, Merck and Tibotec. R. D. M. reports receiving consulting fees from Bristol-Myers Squibb and GlaxoSmithKline, lecture fees from Gilead, and grant support from Pfizer, Merck, Gilead, and Agency for Healthcare Research and Quality. All other authors: no conflicts.
ISSN:0022-1899
1537-6613
DOI:10.1093/infdis/jir421